Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Condition: Triple Negative Breast Cancer (TNBC) Interventions: Biological: spartalizumab; Biological: LAG525; Drug: NIR178; Drug: capmatinib; Biological: MCS110; Biological: canakinumab Sponsor: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials